| Autor: |
Atkinson, V.G. Quaglino, P. Aglietta, M. Del Vecchio, M. Depenni, R. Consoli, F. Bafaloukos, D. Ferrucci, P.F. Tulyte, S. Krajsová, I. Ascierto, P.A. Gueli, R. Arance, A. Gogas, H. Banerjee, H. Saliba, T. de Jong, E. Neyns, B. |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Popis: |
The dabrafenib plus trametinib (dab + tram) combination has demonstrated durable longterm efficacy in patients with BRAF V600–mutant metastatic melanoma. However, real-world data characterizing patients with long-term benefit are limited. DESCRIBE III was a global, observational, retrospective, chart review study in patients with unresectable or metastatic melanoma treated with dab monotherapy and/or dab + tram combination therapy as part of the Named Patient Program or Individual Patient Program. Overall, 509 patients were enrolled. Patients were categorized into three groups based on their observed treatment duration: long-term (on therapy ≥12 months), intermediate (on therapy ≥6 months and |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
